A newly proposed “osteosarcoma spatial score” that captures the ratio of immune–tumour juxtaposition to immune-desert areas stratifies five-year survival more accurately than PD-L1 staining and is being built into biomarker-driven trials [56]. The gene discussed is CD274; the disease is neoplasm.